{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:18:19Z","timestamp":1790633899055,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with neurofibromatosis type 1 (NF1) can develop plexiform neurofibromas (PN). Large tumor burden is a predictor for the development of malignant peripheral nerve sheath tumors. Whole-body magnetic resonance imaging (WB-MRI) is the recommended imaging method for the evaluation of PN. WB-MRI is recommended for NF1 patients at transition from adolescence to adulthood. In the absence of internal PN further follow-up WB-MRI is not considered necessary. PN are often detected in early childhood, leading to the assumption that they may be congenital lesions. It remains unclear whether this invariably applies to all patients or whether patients who initially displayed no tumors can still develop PN over time. Therefore, we retrospectively reviewed WB-MRI scans of pediatric patients with NF1 without initial tumor burden and compared these with long-term follow-up scans for presence of newly developed PN.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed WB-MRI scans of 17 NF1-children (twelve male; median age at initial scan: 9 [IQR 6.1\u201311.9] years) who initially displayed no PN. MRI scans with a follow-up interval of at least 6\u00a0years (median follow-up interval: 9 [IQR 5.6\u201312.4] years) were reviewed in consensus by two radiologists regarding the development of new PN over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>New PN were identified in two out of 17 children without initial tumor burden in follow-up examinations. One of these two patients developed two larger distinct PN of 4.5\u00a0cm on the right upper arm and of 2.5\u00a0cm on the left thoracic wall between the age of ten and twelve. The second child developed multiple smaller PN along the major peripheral nerves between the age of eleven and 16. In addition, 15 of the children without initial tumor burden did not develop any distinct tumors for a period of at least 6\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicate that PN can be newly detected in pediatric patients over time, even if no PN were detected on initial MRI scans. Therefore, it seems reasonable to perform at least a second MRI in pediatric NF1 patients at transition to adulthood, even if they did not display any tumor burden on initial MRI, and when the MRI was performed significantly under the age of 18. With this approach, tumors that may have developed between scans can be detected and patients at risk for complications can be identified.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03420-6","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:04:05Z","timestamp":1730739845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumors"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4991-8544","authenticated-orcid":false,"given":"Marie-Lena","family":"Schmalhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3596-5932","authenticated-orcid":false,"given":"Said","family":"Farschtschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-4551","authenticated-orcid":false,"given":"Lan","family":"Kluwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Felix","family":"Mautner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-3868","authenticated-orcid":false,"given":"Gerhard","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-1346","authenticated-orcid":false,"given":"Lennart","family":"Well","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-2321","authenticated-orcid":false,"given":"Inka","family":"Ristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"issue":"1","key":"3420_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1542\/peds.2007-3204","volume":"123","author":"VC Williams","year":"2009","unstructured":"Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124\u201333.","journal-title":"Pediatrics"},{"issue":"1","key":"3420_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89(1):1\u20136.","journal-title":"Am J Med Genet"},{"issue":"2","key":"3420_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152a","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152a(2):327\u201332.","journal-title":"Am J Med Genet A."},{"issue":"1","key":"3420_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005;141(1):71\u20134.","journal-title":"Arch Dermatol"},{"issue":"11","key":"3420_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1136\/jmg.26.11.712","volume":"26","author":"S Huson","year":"1989","unstructured":"Huson S, Compston D, Harper P. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet. 1989;26(11):712\u201321.","journal-title":"J Med Genet."},{"issue":"4908","key":"3420_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1126\/science.2543076","volume":"244","author":"JW Fountain","year":"1989","unstructured":"Fountain JW, Wallace MR, Bruce MA, Seizinger BR, Menon AG, Gusella JF, et al. Physical mapping of a translocation breakpoint in neurofibromatosis. Science (New York, NY). 1989;244(4908):1085\u20137.","journal-title":"Science (New York, NY)"},{"issue":"8","key":"3420_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/088307380201700804","volume":"17","author":"D Viskochil","year":"2002","unstructured":"Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol. 2002;17(8):562\u201370.","journal-title":"J Child Neurol."},{"issue":"4","key":"3420_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1215\/15228517-2008-011","volume":"10","author":"VF Mautner","year":"2008","unstructured":"Mautner VF, Asuagbor FA, Dombi E, F\u00fcnsterer C, Kluwe L, Wenzel R, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol. 2008;10(4):593\u20138.","journal-title":"Neuro Oncol"},{"issue":"6","key":"3420_CR9","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/foc.2007.22.6.6","volume":"22","author":"S Lwu","year":"2007","unstructured":"Lwu S, Midha R. Clinical examination of brachial and pelvic plexus tumors. Neurosurg Focus. 2007;22(6):E5.","journal-title":"Neurosurg Focus"},{"issue":"3","key":"3420_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10143-015-0620-8","volume":"38","author":"J Gosk","year":"2015","unstructured":"Gosk J, Gutkowska O, Mazurek P, Koszewicz M, Zi\u00f3\u0142kowski P. Peripheral nerve tumours: 30-year experience in the surgical treatment. Neurosurg Rev. 2015;38(3):511\u201320.","journal-title":"Neurosurg Rev."},{"issue":"1","key":"3420_CR11","doi-asserted-by":"publisher","first-page":"e1982","DOI":"10.1097\/GOX.0000000000001982","volume":"7","author":"LA Taylor","year":"2019","unstructured":"Taylor LA, Lewis VL Jr. Neurofibromatosis type 1: review of cutaneous and subcutaneous tumor treatment on quality of life. Plast Reconstr Surg Glob Open. 2019;7(1):e1982.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"3","key":"3420_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0883073817749367","volume":"33","author":"V Domon-Archambault","year":"2018","unstructured":"Domon-Archambault V, Gagnon L, Beno\u00eet A, Perreault S. Psychosocial features of neurofibromatosis type 1 in children and adolescents. J Child Neurol. 2018;33(3):225\u201332.","journal-title":"J Child Neurol"},{"issue":"1","key":"3420_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13023-022-02174-3","volume":"17","author":"E Kang","year":"2022","unstructured":"Kang E, Kim YM, Choi Y, Lee Y, Kim J, Choi IH, et al. Whole-body MRI evaluation in neurofibromatosis type 1 patients younger than 3 years old and the genetic contribution to disease progression. Orphanet J Rare Dis. 2022;17(1):24.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3420_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/(SICI)1096-8628(20000515)92:2<132::AID-AJMG10>3.0.CO;2-6","volume":"92","author":"DJ Waggoner","year":"2000","unstructured":"Waggoner DJ, Towbin J, Gottesman G, Gutmann DH. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet. 2000;92(2):132\u20135.","journal-title":"Am J Med Genet"},{"issue":"9","key":"3420_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie A, Fox E, Balis F, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007;68(9):643\u20137.","journal-title":"Neurology"},{"issue":"2","key":"3420_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2008.061051","volume":"46","author":"T Tucker","year":"2009","unstructured":"Tucker T, Friedman JM, Friedrich RE, Wenzel R, F\u00fcnsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009;46(2):81\u20135.","journal-title":"J Med Genet"},{"issue":"12","key":"3420_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/gcc.20921","volume":"50","author":"E Beert","year":"2011","unstructured":"Beert E, Brems H, Dani\u00ebls B, De Wever I, Van Calenbergh F, Schoenaers J, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosom Cancer. 2011;50(12):1021\u201332.","journal-title":"Genes Chromosom Cancer"},{"issue":"8","key":"3420_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuonc\/noz028","volume":"21","author":"A Pemov","year":"2019","unstructured":"Pemov A, Hansen NF, Sindiri S, Patidar R, Higham CS, Dombi E, et al. Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol. 2019;21(8):981\u201392.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3420_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pbc.24212","volume":"60","author":"H Meany","year":"2013","unstructured":"Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, et al. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer. 2013;60(1):59\u201364.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"3420_CR20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","volume":"22","author":"S Akshintala","year":"2020","unstructured":"Akshintala S, Baldwin A, Liewehr DJ, Goodwin A, Blakeley JO, Gross AM, et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro Oncol. 2020;22(9):1368\u201378.","journal-title":"Neuro Oncol"},{"issue":"6","key":"3420_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","volume":"20","author":"CS Higham","year":"2018","unstructured":"Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol. 2018;20(6):818\u201325.","journal-title":"Neuro Oncol"},{"issue":"5","key":"3420_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311\u20134.","journal-title":"J Med Genet"},{"issue":"2","key":"3420_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","volume":"116","author":"R Nguyen","year":"2014","unstructured":"Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner VF. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol. 2014;116(2):307\u201313.","journal-title":"J Neurooncol"},{"issue":"1","key":"3420_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1245\/s10434-012-2573-2","volume":"20","author":"J LaFemina","year":"2013","unstructured":"LaFemina J, Qin LX, Moraco NH, Antonescu CR, Fields RC, Crago AM, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol. 2013;20(1):66\u201372.","journal-title":"Ann Surg Oncol"},{"issue":"7 Suppl 1","key":"3420_CR25","first-page":"S31","volume":"87","author":"S Ahlawat","year":"2016","unstructured":"Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016;87(7 Suppl 1):S31\u20139.","journal-title":"Neurology"},{"key":"3420_CR26","doi-asserted-by":"publisher","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","volume":"56","author":"C Carton","year":"2023","unstructured":"Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"3420_CR27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"Neurofibromatosis N","year":"1988","unstructured":"Neurofibromatosis N. Conference statement. National Institutes of Health consensus development conference. Arch Neurol. 1988;45(5):575\u20138.","journal-title":"Arch Neurol."},{"key":"3420_CR28","unstructured":"The HGVS Nomenclature. https:\/\/hgvs-nomenclature.org\/stable\/. Accessed 15 Aug 2024."},{"key":"3420_CR29","unstructured":"Evidence-based network for the interpretation of germline mutant alleles. https:\/\/enigmaconsortium.org. Accessed 15 Aug 2024."},{"issue":"12","key":"3420_CR30","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1055\/s-0035-1553505","volume":"187","author":"J Salamon","year":"2015","unstructured":"Salamon J, Mautner VF, Adam G, Derlin T. Multimodal imaging in neurofibromatosis type 1-associated nerve sheath tumors. Rofo. 2015;187(12):1084\u201392.","journal-title":"Rofo"},{"issue":"20","key":"3420_CR31","first-page":"354","volume":"117","author":"S Farschtschi","year":"2020","unstructured":"Farschtschi S, Mautner VF, McLean ACL, Schulz A, Friedrich RE, Rosahl SK. The neurofibromatoses. Dtsch Arztebl Int. 2020;117(20):354\u201360.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"3420_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00247-017-3871-4","volume":"48","author":"K Barton","year":"2018","unstructured":"Barton K, Nickerson JP, Higgins T, Williams RK. Pediatric anesthesia and neurotoxicity: what the radiologist needs to know. Pediatr Radiol. 2018;48(1):31\u20136.","journal-title":"Pediatr Radiol"},{"issue":"5","key":"3420_CR33","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1148\/rg.275075023","volume":"27","author":"FM Akisik","year":"2007","unstructured":"Akisik FM, Sandrasegaran K, Aisen AM, Lin C, Lall C. Abdominal MR imaging at 3.0 T. Radiographics. 2007;27(5):1433\u201344.","journal-title":"Radiographics"},{"issue":"7","key":"3420_CR34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1148\/rg.287075154","volume":"28","author":"KJ Chang","year":"2008","unstructured":"Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. Radiographics. 2008;28(7):1983\u201398.","journal-title":"Radiographics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03420-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03420-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:09:51Z","timestamp":1730884191000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03420-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03420-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has been approved by the local Institutional Review Board (\u00c4rztekammer Hamburg; 2023-300412-WF; app. date 23.11.2023) for retrospective analysis of the available data which complied with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was given from all NF1 patients at the initial consultation at the neurofibromatosis clinic for the anonymized analysis and scientific use of the MRI data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SF and LW have received honoraria for talks and advisory from AstraZeneca and Alexion and SF is chairman of the German lay organization \u201cBundesverband Neurofibromatose\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}